56 A new study published in the journal JAMA Oncology found a strong link between men with advanced and metastatic prostate cancer (PCa) who take androgen receptor signalling inhibitors (ARSI) and a higher risk of cardiovascular (CV) events. The study, conducted by Dr Omar El-Taji and colleagues, systematically reviewed and analysed data from 24 randomised clinical trials (RCTs) to better understand the cardiovascular implications of these widely used therapies. Androgen receptor signalling inhibitors have revolutionised the treatment landscape for advanced prostate cancer. Medications such as abiraterone, apalutamide, darolutamide, and enzalutamide have been shown to improve survival rates significantly when used in combination with standard androgen deprivation therapy (ADT). However, the potential cardiovascular toxicity of these drugs has remained a critical concern, especially as their use becomes more prevalent in treating both hormone-sensitive and castration-resistant prostate cancer. Dr El-Taji’s team performed systematic searches across multiple databases, including PubMed, Scopus, Web of Science, EMBASE, and ClinicalTrials.gov, up to May 2023. Their goal was to assess the incidence of CV events associated with the addition of ARSI to standard of care (SOC) in various stages of prostate cancer. The meta-analysis included 24 studies with a total of 22,166 patients. The median age of participants ranged from 63 to 77 years, with a median follow-up time spanning from 3.9 to 96 months. The primary outcomes focused on the incidence of all grade CV events and grade 3 or higher CV events. Secondary outcomes included specific conditions such as hypertension, acute coronary syndrome (ACS), cardiac dysrhythmia, CV death, cerebrovascular events, and venous thromboembolism. The findings were striking. The use of ARSI therapy was associated with a 75% increased risk of all grade CV events (risk ratio [RR], 1.75; 95% CI, 1.50-2.04) and a more than two-fold increased risk of grade 3 or higher CV events (RR, 2.10; 95% CI, 1.72-2.55). Moreover, ARSI therapy was linked to an increased risk of specific grade 3 or higher CV conditions, including: Hypertension (RR, 2.25; 95% CI, 1.74–2.90) Acute coronary syndrome (RR, 1.93; 95% CI, 1.43–1.60) Cardiac dysrhythmia (RR, 1.64; 95% CI, 1.23–2.17) Cerebrovascular events (RR, 1.86; 95% CI, 1.34–2.59) CV-related death (RR, 2.02; 95% CI, 1.32–3.10) Subgroup analyses revealed that the increased risk of CV events was consistent across different stages of prostate cancer. There was a 2.26 times higher risk of all grade CV events for people with locally advanced hormone-sensitive prostate cancer (M0 HSPC), compared to people with metastatic castration-resistant prostate cancer (M1 CRPC). The risk increase for people with M1 CRPC was 1.46 times higher, but it was still significant. The study also noted significant heterogeneity in the risk ratios, suggesting that the degree of CV risk might vary depending on the specific ARSI agent used. For instance, the combination of abiraterone acetate and enzalutamide presented the highest risk for CV events (RR, 2.92; 95% CI, 2.59–3.30), while darolutamide exhibited the lowest risk increase (RR, 1.30; 95% CI, 1.09–1.54). These findings underscore the importance of monitoring cardiovascular health in patients undergoing ARSI therapy. Given the significant advantages these treatments have for cancer survival, it is crucial for healthcare professionals to weigh these advantages against the risk of serious cardiovascular side effects. The study suggests that patients with preexisting cardiovascular conditions or those at high risk for CV events should be carefully evaluated before initiating ARSI therapy. Regular cardiovascular monitoring and proactive management of CV risk factors could help mitigate these risks and improve overall patient outcomes.